Compare NPKI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | ESPR |
|---|---|---|
| Founded | 1932 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 898.5M |
| IPO Year | N/A | 2013 |
| Metric | NPKI | ESPR |
|---|---|---|
| Price | $12.20 | $3.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $14.17 | $6.67 |
| AVG Volume (30 Days) | 693.6K | ★ 6.5M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $259,372,000.00 | ★ $303,802,000.00 |
| Revenue This Year | $26.96 | $25.45 |
| Revenue Next Year | $13.16 | N/A |
| P/E Ratio | $32.40 | ★ N/A |
| Revenue Growth | ★ 25.65 | 2.83 |
| 52 Week Low | $4.76 | $0.69 |
| 52 Week High | $14.00 | $4.13 |
| Indicator | NPKI | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 59.47 |
| Support Level | $12.21 | $3.63 |
| Resistance Level | $12.57 | $4.13 |
| Average True Range (ATR) | 0.35 | 0.20 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 13.22 | 64.00 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.